BriaCell Therapeutics Corp

As of April 30, 2026, BriaCell Therapeutics Corp carries a market capitalization of 41.33M, placing it among publicly traded companies globally. Its enterprise value stands at 9.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, BriaCell Therapeutics Corp has 7.25M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, BriaCell Therapeutics Corp maintains a current ratio of 7.07, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended April 30, 2026, BriaCell Therapeutics Corp posted a negative return on equity (ROE) of -207.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -157.60, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 18.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, BriaCell Therapeutics Corp's stock has declined approximately 71.48% over the past 52 weeks. The 50-day moving average sits at 5.30, while the 200-day moving average is 5.45.

Over the twelve months ended April 30, 2026, BriaCell Therapeutics Corp generated - - in revenue and converted that into -39.00M in net income, yielding earnings per share of -12.82. EBITDA reached -40.33M, while operating income came in at -40.49M.

These figures are as of April 30, 2026. Total book value stands at 32.68M, with working capital of 29.62M providing operational flexibility.

BriaCell Therapeutics Corp produced -40.56M in operating cash flow over the twelve months ended April 30, 2026.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -231.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -139.99, meaning BriaCell Therapeutics Corp raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BriaCell Therapeutics Corp's most recent stock split took place on August 25, 2025 with a 10:1 split ratio.

As of April 30, 2026, BriaCell Therapeutics Corp has an Altman Z-Score of -4.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.